29 Sep Life Length receives €3.1 million from the E.U.
Life Length has been awarded €3.1 million by the European Union as a Phase 2 grant under the prestigious and highly competitive Horizon 2020 for its ONCOCHECK project which will fund clinical studies of this valuable biomarker in cancer treatment.
Bilbao, Spain, September 29, 2016 – Life Length, world leader in telomere diagnostics, announced today that it has been granted €3.1 million from the European Union to carry out clinical studies involving 1,200 adults and 300 children suffering from one of multiple types of cancer over the next two years. These cancers include prostate, lung and leukemia, among others.
In 2015, Life Length received €50,000 as a Phase 1 grant which has been used to develop the Phase 2 project. Phase 2 projects are highly competitive; within the life sciences sector, the Horizon 2020 program funds just 8 to 10 projects per year and receives thousands of proposals from companies throughout Europe.
Life Length will carry out the project in partnership with a number of Spain’s most important hospitals including University Hospital 12 de Octubre, University Hospital Puerta de Hierro, University Hospital Niño Jesús, Vall d’Hebron Hospital and the Centro Integral Oncológico Clara Campal from which patients will be recruited.
The objective of the ONCOCHECK project is to demonstrate the clinical utility as a prognostic and companion biomarker in the treatment of these cancers using Life Length’s proprietary Telomere Analysis Technology® (TAT®) test which can be performed from a simple blood sample.
There are over 7,000 clinical publications on cancer and telomeres and many papers have shown that telomere length is predicative of cancer evolution and aggressiveness but to date no studies of such large scope and with such a precise, accurate and reproducible assay have been conducted. Life Length’s unique dual status as a U.S. Federally certified “CLIA” and internationally ISO 15189 accredited diagnostic laboratory means that these studies will be carried out under the highest standards of quality ever performed in large scale telomere diagnostics.
Stephen J. Matlin, CEO of Life Length, noted “the Horizon 2020 Phase 2 €3.1 million grant reflects the two things: the importance that telomeres play in cancer development warranting their measurement for treatment protocols together with the clinical power of our telomere measurement assay which is sensitive and accurate enough for individual patient diagnostic use. Global annual cancer treatments costs exceed $1 trillion, and cancer is poised to overtake cardiovascular disease as the leading cause of death worldwide. We believe that Life Length´s TAT assay, as a simple to perform blood test, can contribute to improving patient treatment and outcomes for millions of individuals facing diverse cancers across the globe. Life Length is grateful that the European Union concurs in this view and have given us their support.”
About Life Length
Originally a spin-off of the Spanish National Cancer Research Center, with the support of the Botín Foundation, Life Length offers a number of proprietary tests for measuring cellular senescence, a crucial biomarker for establishing biological age, for early detection of chronic diseases and for risk stratification. Life Length is the only company in the world able to measure telomeres individually at the chromosomal level with its Telomere Analysis Technology® (TAT®). Life Length provides its testing services to the pharmaceutical and related industries for drug and product R&D and clinical studies, as well as to physicians working in preventive and personalized medicine in patient care together in such fields as cardiology and oncology in which telomeres have been shown to make a significant contribution in disease development. Life Length is accredited by the U.S. Federal Government under CLIA as a clinical laboratory under the CLIA legislation and also holds the prestigious IS0 15189 accreditation. For more information, please visit www.lifelength.com.
For media inquiries:
|Guzmán de Aguilar
Pinies & Aguilar
Tel. +34 690 960 764
Sales & Marketing Director
Tel: +34 91 395 6367
+34 637 724 456